Genetic Technologies Limited (GENE)
USD 0.77
(0.0%)
USD 0.77
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 | 3.9 Million AUD | -35.06% |
| 2023 | 6.01 Million AUD | -32.79% |
| 2022 | 6.47 Million AUD | 2792.02% |
| 2021 | -240.47 Thousand AUD | 0.49% |
| 2020 | -241.64 Thousand AUD | 3.66% |
| 2019 | -250.82 Thousand AUD | -126.31% |
| 2018 | -110.83 Thousand AUD | -524.83% |
| 2017 | 26.08 Thousand AUD | -68.0% |
| 2016 | 81.52 Thousand AUD | -92.73% |
| 2015 | 1.12 Million AUD | -58.9% |
| 2014 | 2.72 Million AUD | 90.44% |
| 2013 | 1.43 Million AUD | -84.74% |
| 2012 | 9.38 Million AUD | -42.23% |
| 2011 | 16.24 Million AUD | 130.69% |
| 2010 | 7.04 Million AUD | 78.77% |
| 2009 | 3.93 Million AUD | -73.47% |
| 2008 | 14.84 Million AUD | 106.35% |
| 2007 | 7.19 Million AUD | 292.75% |
| 2006 | 1.83 Million AUD | -62.27% |
| 2005 | 4.85 Million AUD | 716.49% |
| 2004 | 594.57 Thousand AUD | -93.58% |
| 2003 | 9.26 Million AUD | -29.32% |
| 2002 | 13.1 Million AUD | 132.68% |
| 2001 | 5.63 Million AUD | 40.17% |
| 2000 | 4.01 Million AUD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 1.55 Million AUD | 227.37% |
| 2024 FY | -4.3 Million AUD | -199.03% |
| 2024 Q2 | -1.98 Million AUD | 0.0% |
| 2024 Q3 | 1.39 Million AUD | 170.56% |
| 2024 Q4 | 1.39 Million AUD | 0.0% |
| 2023 FY | 4.35 Million AUD | -32.79% |
| 2023 Q1 | 1.41 Million AUD | -51.63% |
| 2023 Q3 | 1.59 Million AUD | 202.9% |
| 2023 Q4 | -1.22 Million AUD | -176.88% |
| 2023 Q2 | -1.54 Million AUD | -209.28% |
| 2022 Q3 | 1.93 Million AUD | 161.65% |
| 2022 Q2 | 741.18 Thousand AUD | -36.27% |
| 2022 Q4 | 2.92 Million AUD | 50.84% |
| 2022 FY | 6.47 Million AUD | 2792.02% |
| 2022 Q1 | 1.16 Million AUD | 415.36% |
| 2021 Q2 | -270.22 Thousand AUD | -224.42% |
| 2021 Q1 | -83.29 Thousand AUD | 42.51% |
| 2021 FY | -240.47 Thousand AUD | 0.49% |
| 2021 Q4 | -368.79 Thousand USD | -156.49% |
| 2021 Q3 | 652.86 Thousand AUD | 341.6% |
| 2020 Q4 | -144.88 Thousand AUD | -507.06% |
| 2020 FY | -241.64 Thousand AUD | 3.66% |
| 2020 Q2 | -206.07 Thousand AUD | -112.54% |
| 2020 Q3 | -23.86 Thousand AUD | 88.42% |
| 2020 Q1 | -96.95 Thousand AUD | 65.14% |
| 2019 Q1 | -30.63 Thousand AUD | -12.01% |
| 2019 FY | -250.82 Thousand AUD | -126.31% |
| 2019 Q2 | -30.63 Thousand AUD | 0.0% |
| 2019 Q3 | -94.77 Thousand AUD | -209.36% |
| 2019 Q4 | -278.12 Thousand USD | -193.45% |
| 2018 Q4 | -27.35 Thousand AUD | -0.0% |
| 2018 FY | -110.83 Thousand AUD | -524.83% |
| 2018 Q2 | -28.06 Thousand AUD | 0.0% |
| 2018 Q1 | -28.06 Thousand AUD | -19.7% |
| 2018 Q3 | -27.35 Thousand AUD | 2.55% |
| 2017 Q4 | -23.44 Thousand AUD | 0.0% |
| 2017 Q3 | -23.44 Thousand AUD | -164.25% |
| 2017 Q2 | 36.49 Thousand AUD | 0.0% |
| 2017 Q1 | 36.49 Thousand AUD | 60.41% |
| 2017 FY | 26.08 Thousand AUD | -68.0% |
| 2016 Q4 | 22.74 Thousand AUD | 0.0% |
| 2016 Q2 | 18.01 Thousand AUD | 0.0% |
| 2016 Q1 | 18.01 Thousand AUD | -91.03% |
| 2016 Q3 | 22.74 Thousand AUD | 26.29% |
| 2016 FY | 81.52 Thousand AUD | -92.73% |
| 2015 FY | 1.12 Million AUD | -58.9% |
| 2015 Q4 | 200.74 Thousand AUD | 0.0% |
| 2015 Q3 | 200.74 Thousand AUD | 41.48% |
| 2015 Q2 | 141.88 Thousand AUD | 0.0% |
| 2015 Q1 | 141.88 Thousand AUD | -72.82% |
| 2014 Q4 | 522.11 Thousand AUD | 0.0% |
| 2014 FY | 2.72 Million AUD | 90.44% |
| 2014 Q2 | 301.55 Thousand AUD | -0.0% |
| 2014 Q1 | 301.55 Thousand AUD | 406.03% |
| 2014 Q3 | 522.11 Thousand AUD | 73.14% |
| 2013 Q1 | -385.51 Thousand AUD | 0.0% |
| 2013 FY | 1.43 Million AUD | -84.74% |
| 2013 Q3 | -98.53 Thousand AUD | 74.44% |
| 2013 Q2 | -385.51 Thousand AUD | -0.0% |
| 2013 Q4 | -98.53 Thousand AUD | 0.0% |
| 2012 FY | 9.38 Million AUD | -42.23% |
| 2012 Q2 | - AUD | 0.0% |
| 2012 Q3 | - AUD | 0.0% |
| 2012 Q4 | - AUD | 0.0% |
| 2011 Q2 | - AUD | 0.0% |
| 2011 FY | 16.24 Million AUD | 130.69% |
| 2011 Q4 | - AUD | 0.0% |
| 2010 FY | 7.04 Million AUD | 78.77% |
| 2010 Q4 | - AUD | 0.0% |
| 2009 FY | 3.93 Million AUD | -73.47% |
| 2009 Q4 | - AUD | 0.0% |
| 2008 FY | 14.84 Million AUD | 106.35% |
| 2008 Q1 | 4.42 Million AUD | -10.72% |
| 2008 Q2 | 3.65 Million AUD | -17.4% |
| 2008 Q4 | 3.33 Million AUD | -49.76% |
| 2008 Q3 | 6.63 Million AUD | 81.61% |
| 2007 Q3 | 4.24 Million AUD | 268.34% |
| 2007 Q4 | 4.95 Million AUD | 16.76% |
| 2007 FY | 7.19 Million AUD | 292.75% |
| 2007 Q2 | 1.15 Million AUD | -57.5% |
| 2007 Q1 | 2.7 Million AUD | 867.29% |
| 2006 Q3 | 2.56 Million AUD | -9.82% |
| 2006 Q4 | 279.99 Thousand AUD | -89.1% |
| 2006 Q1 | 3.37 Million AUD | 426.69% |
| 2006 FY | 1.83 Million AUD | -62.27% |
| 2006 Q2 | 2.84 Million AUD | -15.61% |
| 2005 FY | 4.85 Million AUD | 716.49% |
| 2005 Q4 | -1.03 Million AUD | -129.1% |
| 2005 Q1 | 3.76 Million AUD | 0.0% |
| 2005 Q2 | 2.28 Million AUD | -39.37% |
| 2005 Q3 | 3.55 Million AUD | 55.6% |
| 2004 FY | 594.57 Thousand AUD | -93.58% |
| 2003 FY | 9.26 Million AUD | -29.32% |
| 2002 FY | 13.1 Million AUD | 132.68% |
| 2001 FY | 5.63 Million AUD | 40.17% |
| 2000 FY | 4.01 Million AUD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Bionano Genomics, Inc. | 9.56 Million USD | 59.184% |
| iSpecimen Inc. | 5.1 Million USD | 23.56% |
| Prenetics Global Limited | 8.82 Million USD | 55.781% |
| OpGen, Inc. | -90.69 Thousand USD | 4405.107% |
| Exact Sciences Corporation | 1.84 Billion USD | 99.788% |
| Star Equity Holdings, Inc. | 11.92 Million USD | 67.261% |
| CareDx, Inc | 178.32 Million USD | 97.81% |
| Exagen Inc. | 29.45 Million USD | 86.745% |
| Inotiv, Inc. | 165.44 Million USD | 97.64% |
| Guardant Health, Inc. | 336.89 Million USD | 98.841% |
| Biodesix, Inc. | 36.07 Million USD | 89.177% |
| BioNexus Gene Lab Corp. | 1.32 Million USD | -193.68% |
| Precipio, Inc. | 6.01 Million USD | 35.12% |
| Aspira Women's Health Inc. | 5.26 Million USD | 25.799% |
| Standard BioTools Inc. | 50.45 Million USD | 92.261% |
| 23andMe Holding Co. | 99.37 Million USD | 96.071% |
| Castle Biosciences, Inc. | 174.8 Million USD | 97.766% |
| Personalis, Inc. | 18.2 Million USD | 78.556% |
| Aclaris Therapeutics, Inc. | 13.16 Million USD | 70.349% |
| Applied DNA Sciences, Inc. | 5.53 Million USD | 29.438% |
| T2 Biosystems, Inc. | -8.17 Million USD | 147.79% |
| Neogen Corporation | 463.9 Million USD | 99.158% |
| Natera, Inc. | 492.74 Million USD | 99.208% |
| Myriad Genetics, Inc. | 476.4 Million USD | 99.18% |
| ICON Public Limited Company | 1.81 Billion USD | 99.785% |
| NeoGenomics, Inc. | 244.6 Million USD | 98.404% |
| Star Equity Holdings, Inc. | 11.92 Million USD | 67.261% |
| IDEXX Laboratories, Inc. | 2.18 Billion USD | 99.822% |
| RadNet, Inc. | 93 Million USD | 95.802% |
| MDxHealth SA | 43.92 Million USD | 91.112% |
| Check-Cap Ltd. | -212 Thousand USD | 1941.733% |
| Twist Bioscience Corporation | 133.34 Million USD | 97.072% |
| Psychemedics Corporation | 8.41 Million USD | 53.59% |
| Fulgent Genetics, Inc. | 104.45 Million USD | 96.262% |
| Sera Prognostics, Inc. | 96 Thousand USD | -3967.16% |
| OPKO Health, Inc. | 318.12 Million USD | 98.773% |
| Illumina, Inc. | 2.74 Billion USD | 99.858% |
| DarioHealth Corp. | 5.98 Million USD | 34.751% |
| ENDRA Life Sciences Inc. | -275.45 Thousand USD | 1517.484% |
| Medpace Holdings, Inc. | 524.5 Million USD | 99.256% |
| Prenetics Global Limited | 8.82 Million USD | 55.781% |
| Intelligent Bio Solutions Inc. | 1.42 Million USD | -173.878% |
| Mainz Biomed B.V. | 509.65 Thousand USD | -666.095% |
| bioAffinity Technologies, Inc. | 791.61 Thousand USD | -393.229% |
| Trinity Biotech plc | 19.45 Million USD | 79.926% |
| Neuronetics, Inc. | 51.7 Million USD | 92.449% |
| Sotera Health Company | 577.15 Million USD | 99.323% |
| bioAffinity Technologies, Inc. | 791.61 Thousand USD | -393.229% |